A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects

Liver International

Volumn 34, Issue 6, 2014, Pages

  Gardner, Stephen ^a   Cutrell, Amy ^a   Elko Simms, Cindy ^b   Adkison, Kimberly ^a   Hamatake, Robert ^a   Walker, Jill ^a   Rodriguez Torres, Maribel ^c   Hong, Zhi ^a  

^a GLAXOSMITHKLINE   (United States)

^b Pharmaceutical Product Development   (United States)

^c Fundacion de Investigacion   (Puerto Rico)

Author keywords

Direct acting antiviral; GSK2336805; Hepatitis C; Peginterferon alfa 2a; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; GSK 2336805; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; BIOLOGICAL MARKER; CARBAMIC ACID DERIVATIVE; GSK2336805; MACROGOL DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; RECOMBINANT PROTEIN; VALINE; VIRUS PROTEIN; VIRUS RNA;

ADULT; AGED; ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; CHILL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLICULITIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION; LEUKOPENIA; LUNG DISEASE; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PUERTO RICO; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; UNITED STATES; VIRUS LOAD; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CARBAMATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PHENOTYPE; POLYETHYLENE GLYCOLS; PUERTO RICO; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; UNITED STATES; VALINE; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84902553184     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12334     Document Type: Article

References (10)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29: 74-81.
2. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
3. Hoofnagle JH. Course and outcome of hepatitis C. Hepatol 2002; 36: S21-9.
4. Brass V, Moradpour D, Blum HE. Molecular virology of hepatitis C virus (HCV): 2006 update. Int J Med Sci 2006; 3: 29-34.
5. Lawrence SP. Advances in the treatment of hepatitis C. Adv Intern Med 2000; 45: 65-105.
6. Bechtel J, Crosby R, Wang A, et al. In vitro profiling of GSK2336805, a potent and selective inhibitor of HCV NS5a. Annual Meeting of the European Association for the Study of the Liver (EASL), 1st April 2011, P2.08a; poster 764.
7. Wilfret D, Walker J, Adkison K, et al. Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus NS5A, in healthy subjects and subjects chronically infected with genotype 1 hepatitis C virus. Antimicrob Agents Chemother 2013; 57: 5037-44.
8. Yu JW, Wang GQ, Sun LJ, et al. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpa-2a and ribavirin. J Gastroenterol Hepatol 2007; 22: 832-6.
9. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-60.
10. Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomized, parallel-group, double-blind, placebo-controlled, dose-finding, Phase 2a trial. Lancet Infect Dis 2012; 12: 671-7.